ドセタキセルの市場規模、シェア、動向分析レポート：適応症別、流通チャネル別、地域別、セグメント予測、2025年～2030年

ドセタキセル市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のドセタキセルの市場規模は2030年までに18億5,000万米ドルに達し、予測期間中にCAGR5.75％で成長すると予測されています。同市場は、緩やかな成長にもかかわらず、世界のがん罹患率の上昇、特に乳がん、肺がん、前立腺がんなど、ドセタキセルが第一選択薬または第二選択薬として使用され続けている疾患によって支えられています。標的治療薬の採用が増加しているため拡大には限界がありますが、検診プログラムの改善、がんに対する意識の高まり、費用対効果の高い化学療法への需要が、この薬剤の関連性に寄与しています。2025年から2030年にかけて、乳がん分野はCAGR5.69％で成長し、6億1,108万米ドルに達すると予測され、ホルモン不応性前立腺がんと胃腺がんは緩やかな成長率になると予測されています。

ドセタキセルの臨床的統合は依然として強力です。例えば、2025年には米国の乳がん症例数は31万9,000例を超えると予想されています。早期に発見された場合の5年生存率は99%であり、スクリーニングの取り組みは、転移性および早期治療における一貫したドセタキセルの使用を支えています。同様に、非小細胞肺がん（NSCLC）とホルモン抵抗性前立腺がんの高い発生率も、持続的な需要を支えています。ジェネリック医薬品や特殊製剤の上市により、細分化も進んでいます。2025年2月、Zydus LifesciencesはZhuhai Beihai Biotechと、2024年に505（b）（2）パスウェイで承認されたアルブミンベースのドセタキセル製剤「BEIZRAY」の米国における商業化契約を締結しました。年間目標数量は53万1,000個で、合成賦形剤を使用しないため副作用が少ないです。

さらに、パイプラインのデータは、併用レジメンでの開発の継続を示唆しています。2027年から2032年にかけて、ドセタキセルとDS-1062a（Daiichi Sankyo）、ダラクソンラシブ（Revolution Medicines）、カピバセルチブ（AstraZeneca）などの薬剤を併用する試験が、NSCLC、前立腺がん、乳がん、胃がんなどを対象に実施されます。これらの試験にはNovartis、Sanofi、GSK、CSPC、Miratiなどのスポンサーが関与しており、世界企業が積極的に関与していることを示しています。

業界動向は、経口ドセタキセルや徐放性ドセタキセルのようなデリバリーや製剤の革新を示す一方、生物学的同等性試験や規制当局の精査のような障壁が新規参入を抑制しています。ジェネリック医薬品が利用可能であるにもかかわらず、厳しい基準と確立された競合が情勢を形成しています。全体として、ドセタキセルは、世界の臨床使用、進行中のパイプラインへの関心、進化するパートナーシップに支えられ、腫瘍学プロトコールの中核的な要素であり続けています。

ドセタキセル市場レポートハイライト

• 適応症別では、乳がんがドセタキセル業界を支配し、2024年の売上シェアの33.11%を占めました。この成長は、世界の有病率の高さ、確立された治療プロトコール、治療におけるドセタキセルの強力な臨床効果に起因します。
• 販売チャネル別では、病院薬局が市場をリードし、2024年には56.00％の売上シェアを占めました。これは、がん治療プロトコルの管理や化学療法の実施において中心的な役割を担っているためです。
• 主な市場企業は、Phyton Biotech LLC、Rochem International Inc.、Alchem International Pvt Ltd、LGM Pharma、HRV Global Life Sciencesなどです。
• 2025年2月、Novo Nordiskは、FDAが非小細胞肺がん（NSCLC）と乳がんの供給不足の解消を宣言し、米国の供給が需要を満たしていることを確認したと発表しました。同社は生産拡大のために65億米ドルを投資し、AIを活用した「Find My Meds」アプリを開始しました。Novo Nordiskは偽造医薬品に警告を発し、FDA承認のドセタキセル医薬品の責任ある使用を強調します。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ドセタキセル市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 ドセタキセル市場：適応症ビジネス分析

• 適応症市場シェア、2024年・2030年
• 適応症セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• 乳がん
• 非小細胞肺がん（NSCLC）
• ホルモン抵抗性前立腺がん
• 胃腺がん
• 頭頸部扁平上皮がん

第5章 ドセタキセル市場：流通チャネルビジネス分析

• 流通チャネル市場シェア、2024年・2030年
• 流通チャネルセグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• オンライン薬局

第6章 ドセタキセル市場：地域推定・動向分析

• 地域別市場シェア分析、2024年・2030年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2018年～2030年：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Phyton Biotech LLC
  • Rochem International Inc
  • Alchem International Pvt Ltd
  • LGM Pharma
  • HRV Global Life Sciences
  • Tenatra Chemie
  • Teva Active Pharmaceutical Ingredients（TAPI）
  • Arch Pharmalabs
  • Aspen Pharmacare
  • ChemGenix Laboratories Pvt Ltd
  • Cipla Ltd

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global docetaxel market, by region, 2018 - 2030 (USD Million)
• Table 4 Global docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 5 Global docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 North America docetaxel market, by country, 2018 - 2030 (USD Million)
• Table 7 North America docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 8 North America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 9 U.S docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 10 U.S docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 Canada docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 12 Canada docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13 Mexico docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 14 Mexico docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Europe docetaxel market, by country, 2018 - 2030 (USD Million)
• Table 16 Europe docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 17 Europe docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 18 UK docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 19 UK docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Germany docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 21 Germany docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 22 France docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 23 France docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 Italy docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 25 Italy docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 26 Spain docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 27 Spain docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 Norway docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 29 Norway docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30 Denmark docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 31 Denmark docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 32 Sweden docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 33 Sweden docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific docetaxel market, by country, 2018 - 2030 (USD Million)
• Table 35 Asia Pacific docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 36 Asia Pacific docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 Japan docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 38 Japan docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 39 China docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 40 China docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 41 India docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 42 India docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 43 Australia docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 44 Australia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 45 South Korea docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 46 South Korea docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 47 Thailand docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 48 Thailand docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 49 Latin America docetaxel market, by country, 2018 - 2030 (USD Million)
• Table 50 Latin America docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 51 Latin America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Brazil docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 53 Brazil docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54 Argentina docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 55 Argentina docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Docetaxel market, by country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 59 South Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 60 South Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 63 UAE docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 64 UAE docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 Kuwait docetaxel market, by indication, 2018 - 2030 (USD Million)
• Table 66 Kuwait docetaxel market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Docetaxel market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Docetaxel market dynamics
• Fig. 12 Docetaxel market: Porter's five forces analysis
• Fig. 13 Docetaxel market: PESTLE analysis
• Fig. 14 Product market, 2018 - 2030 (USD Million)
• Fig. 15 Breast Cancer market, 2018 - 2030 (USD Million)
• Fig. 16 Non-Small Cell Lung Cancer (NSCLC) market, 2018 - 2030 (USD Million)
• Fig. 17 Hormone Refractory Prostate Cancer market, 2018 - 2030 (USD Million)
• Fig. 18 Gastric Adenocarcinoma market, 2018 - 2030 (USD Million)
• Fig. 19 Squamous Cell Carcinoma of the Head and Neck market, 2018 - 2030 (USD Million)
• Fig. 20 Distribution Channel market, 2018 - 2030 (USD Million)
• Fig. 21 Hospital Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 22 Retail Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 23 Online Pharmacies market, 2018 - 2030 (USD Million)
• Fig. 24 Docetaxel market revenue, by region
• Fig. 25 Regional marketplace: Key takeaways
• Fig. 26 North America docetaxel market, 2018 - 2030 (USD Million)
• Fig. 27 U.S. country dynamics
• Fig. 28 U.S. docetaxel market, 2018 - 2030 (USD Million)
• Fig. 29 Canada country dynamics
• Fig. 30 Canada docetaxel market, 2018 - 2030 (USD Million)
• Fig. 31 Mexico country dynamics
• Fig. 32 Mexico docetaxel market, 2018 - 2030 (USD Million)
• Fig. 33 Europe docetaxel market, 2018 - 2030 (USD Million)
• Fig. 34 UK country dynamics
• Fig. 35 UK docetaxel market, 2018 - 2030 (USD Million)
• Fig. 36 Germany country dynamics
• Fig. 37 Germany docetaxel market, 2018 - 2030 (USD Million)
• Fig. 38 France country dynamics
• Fig. 39 France docetaxel market, 2018 - 2030 (USD Million)
• Fig. 40 Italy country dynamics
• Fig. 41 Italy docetaxel market, 2018 - 2030 (USD Million)
• Fig. 42 Spain country dynamics
• Fig. 43 Spain docetaxel market, 2018 - 2030 (USD Million)
• Fig. 44 Norway country dynamics
• Fig. 45 Norway docetaxel market, 2018 - 2030 (USD Million)
• Fig. 46 Sweden country dynamics
• Fig. 47 Sweden docetaxel market, 2018 - 2030 (USD Million)
• Fig. 48 Denmark country dynamics
• Fig. 49 Denmark docetaxel market, 2018 - 2030 (USD Million)
• Fig. 50 Asia Pacific docetaxel market, 2018 - 2030 (USD Million)
• Fig. 51 Japan country dynamics
• Fig. 52 Japan docetaxel market, 2018 - 2030 (USD Million)
• Fig. 53 China country dynamics
• Fig. 54 China docetaxel market, 2018 - 2030 (USD Million)
• Fig. 55 India country dynamics
• Fig. 56 India docetaxel market, 2018 - 2030 (USD Million)
• Fig. 57 Australia country dynamics
• Fig. 58 Australia docetaxel market, 2018 - 2030 (USD Million)
• Fig. 59 South Korea country dynamics
• Fig. 60 South Korea docetaxel market, 2018 - 2030 (USD Million)
• Fig. 61 Thailand country dynamics
• Fig. 62 Thailand docetaxel market, 2018 - 2030 (USD Million)
• Fig. 63 Latin America docetaxel market, 2018 - 2030 (USD Million)
• Fig. 64 Brazil country dynamics
• Fig. 65 Brazil docetaxel market, 2018 - 2030 (USD Million)
• Fig. 66 Argentina country dynamics
• Fig. 67 Argentina docetaxel market, 2018 - 2030 (USD Million)
• Fig. 68 MEA docetaxel market, 2018 - 2030 (USD Million)
• Fig. 69 South Africa country dynamics
• Fig. 70 South Africa docetaxel market, 2018 - 2030 (USD Million)
• Fig. 71 Saudi Arabia country dynamics
• Fig. 72 Saudi Arabia docetaxel market, 2018 - 2030 (USD Million)
• Fig. 73 UAE country dynamics
• Fig. 74 UAE docetaxel market, 2018 - 2030 (USD Million)
• Fig. 75 Kuwait country dynamics
• Fig. 76 Kuwait docetaxel market, 2018 - 2030 (USD Million)
• Fig. 77 Company categorization
• Fig. 78 Company market position analysis
• Fig. 79 Strategic framework

Docetaxel Market Growth And Trends

The global docetaxel market size is anticipated to reach USD 1.85 billion by 2030, growing at a CAGR of 5.75% during the forecast period, according to a new report by Grand View Research, Inc. Despite moderate growth, the market remains sustained by the rising global cancer burden, particularly in breast, lung, and prostate cancers-diseases where docetaxel continues to be used as a first- or second-line treatment. While the increasing adoption of targeted therapies limits expansion, improved screening programs, heightened cancer awareness, and demand for cost-effective chemotherapy contribute to the drug's relevance. From 2025 to 2030, the breast cancer segment is projected to grow at 5.69% CAGR, reaching USD 611.08 million, while hormone-refractory prostate cancer and gastric adenocarcinoma are forecast to grow at a moderate growth rate.

Clinical integration of docetaxel remains strong. For instance, in 2025, breast cancer cases in the U.S. are expected to surpass 319,000. With a 99% five-year survival when detected early, screening initiatives support consistent docetaxel use in metastatic and early-stage therapies. Similarly, high incidence of non-small cell lung cancer (NSCLC) and hormone-resistant prostate cancer supports sustained demand. Fragmentation is also increasing due to product launches by generics and specialty formulations. In February 2025, Zydus Lifesciences entered a U.S. commercialization agreement with Zhuhai Beihai Biotech for BEIZRAY-an albumin-based docetaxel formulation approved via the 505(b)(2) pathway in 2024. With an annual target volume of \~531,000 units, the drug avoids synthetic excipients to reduce side effects.

Moreover, pipeline data suggest continued development in combination regimens. Between 2027 and 2032, trials involving docetaxel with agents such as DS-1062a (Daiichi Sankyo), daraxonrasib (Revolution Medicines), capivasertib (AstraZeneca), and others target NSCLC, prostate, breast, and gastric cancers. These studies involve sponsors like Novartis, Sanofi, GSK, CSPC, and Mirati, indicating active engagement from global players.

Industry trends show innovation in delivery and formulation, such as oral and extended-release docetaxel, while barriers like bioequivalence testing and regulatory scrutiny moderate new entries. Despite the availability of generics, stringent standards and established competition shape the landscape. Overall, docetaxel remains a core component in oncology protocols, supported by global clinical use, ongoing pipeline interest, and evolving partnerships.

Docetaxel Market Report Highlights:

• Based on indication, breast cancer dominated the docetaxel industry, accounting for 33.11% of the revenue share in 2024. This growth is driven by high global prevalence, established treatment protocols, and strong clinical efficacy of docetaxel in therapy.
• Based on distribution channel, hospital pharmacies led the market and accounted for a revenue share of 56.00% in 2024, due to their central role in managing cancer treatment protocols and administering chemotherapy.
• Key market players include Phyton Biotech LLC, Rochem International Inc., Alchem International Pvt Ltd, LGM Pharma, and HRV Global Life Sciences.
• In February 2025, Novo Nordisk announced the FDA has declared the Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer shortage over, confirming U.S. supply meets demand. The company invested USD 6.5 billion to expand production and launched the AI-powered Find My Meds app. Novo Nordisk warns against counterfeit drugs and emphasizes responsible use of its FDA-approved docetaxel medicines.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Docetaxel Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Docetaxel Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Breast Cancer
  • 4.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
• 4.5. Non-Small Cell Lung Cancer (NSCLC)
  • 4.5.1. Non-Small Cell Lung Cancer (NSCLC) Market, 2018 - 2030 (USD Million)
• 4.6. Hormone Refractory Prostate Cancer
  • 4.6.1. Hormone Refractory Prostate Cancer Market, 2018 - 2030 (USD Million)
• 4.7. Gastric Adenocarcinoma
  • 4.7.1. Gastric Adenocarcinoma Market, 2018 - 2030 (USD Million)
• 4.8. Squamous Cell Carcinoma of the Head and Neck
  • 4.8.1. Squamous Cell Carcinoma of the Head and Neck Market, 2018 - 2030 (USD Million)

Chapter 5. Docetaxel Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2030
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6. Docetaxel Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Docetaxel Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. Uk Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Docetaxel Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Phyton Biotech LLC
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Rochem International Inc
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Alchem International Pvt Ltd
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. LGM Pharma
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. HRV Global Life Sciences
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Tenatra Chemie
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Teva Active Pharmaceutical Ingredients (TAPI)
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Arch Pharmalabs
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Aspen Pharmacare
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. ChemGenix Laboratories Pvt Ltd
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Cipla Ltd
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives